TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26510505
Drug: Early chemotherapy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early chemotherapy with docetaxel in addition to androgen deprivation therapy (ADT)
Study: 21940058
Drug: Intracoronary tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary tirofiban administration (10 μg/kg)
Study: 21940058
Drug: Saline control
Normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline control (10 mL)
Study: 20658155
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate (15 mg b.d. for 14 days)
Study: 18327671
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor exemestane alone
Study: 18327671
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor exemestane in combination with antiestrogen tamoxifen
Study: 12800412
Drug: Half-dose Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose Fenofibrate plus Taizhi'an
Study: 12800412
Drug: Full-dose Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose Fenofibrate
Study: 12800412
Drug: Half-dose Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose Simvastatin plus Taizhi'an
Study: 12800412
Drug: Full-dose Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose Simvastatin
Study: 8626839
Drug: Daily somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily somatropin treatment (0.3 mg/kg.week)
Study: 7400374
Drug: Chlorthalidone 50
Normalized name: chlorthalidone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 50 mg plus reserpine 0.25 mg
Study: 7400374
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg plus reserpine 0.125 mg
Study: 30528307
Drug: B +
Normalized name: Vita b + C
Approvals — FDA: no, EMA: no, PMDA: no
Description: B + O suppository
Study: 24432622
Drug: Cardura 4
Normalized name: Cardura 4mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardura 4 mg qd for 8 weeks
Study: 24432622
Drug: Cardura 4
Normalized name: Cardura 4mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardura 4 mg + Tolterodine L‐Tartrate Tablets 4 mg qd for 8 weeks
Study: 21336952
Drug: Artificial gravity
Normalized name: SPECIFIC GRAVITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial gravity (AG) with ergometric exercise (40 W) for 30 min twice per day
Study: 16988136
Drug: Multivitamin supplement
Normalized name: Vi-Daily Multivitamin Supplement Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplement containing folic acid (400 microg) with iron (18 mg)
Study: 16988136
Drug: Multivitamin supplement
Normalized name: Vi-Daily Multivitamin Supplement Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplement containing folic acid (400 microg) without iron
Study: 2188590
Drug: Amifloxacin 200
Normalized name: gatifloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifloxacin 200 mg twice a day
Study: 2188590
Drug: Amifloxacin 400
Normalized name: gatifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifloxacin 400 mg twice a day
Study: 7290416
Drug: Ribostamycin sulphate
Normalized name: Potassium sulphate
DrugBank: Ribostamycin (DB03615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribostamycin sulphate (1000‐2000 mg i.m.)
Study: 7290416
Drug: Gentamycin (160‐240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamycin (160‐240 mg i.m.)
Study: 7290416
Drug: Sodium cephalotin
Normalized name: Cephalothin Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cephalotin (4‐8 g i.v.)
Study: 26628607
Drug: Milnacipran 50
Normalized name: milnacipran 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran 50 mg twice daily for 6 weeks
Study: 26628607
Drug: Milnacipran 50
Normalized name: milnacipran 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran 50 mg twice daily for 6 weeks (subgroup with swollen joint count ≤ 1)
Study: 26552348
Drug: 14-day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day standard regimen of triple therapy for peptic ulcer: omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g, twice per day
Study: 18308147
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with anthracyclines and taxanes
Study: 18308147
Drug: Targeted therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapies (eg, trastuzumab and lapatinib)
Study: 10626563
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) at a total dose of 6 IU/m2/day (0.067 mg/kg/day) and ethinyloestradiol at a dose of 0.05 μg/kg/day
Study: 10626563
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) at a dose of 4 IU/m2/day (0.045 mg/kg/day) for group A, switched to 6 IU/m2/day for group B, and switched to 8 IU/m2/day for group C
Study: 1685942
Drug: Epanolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epanolol (200 mg once daily)
Study: 7036150
Drug: Vaccine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (5 microgram HBsAg per 1ml dose, 3 subcutaneous doses at one-month intervals)
Study: 7036150
Drug: Vaccine (V)
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (V)
Study: 27190374
Drug: Two high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two high flux dialyzers in parallel (blood flow ≥350 mL/min, dialysate flow 800 mL/min)
Study: 27190374
Drug: Standard dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dialysis using one high flux dialyzer (blood flow ≥350 mL/min, dialysate flow of 800 mL/min)
Study: 25684674
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment with antispasmodics or antidiarrhoeal drugs (Group C)
Study: 24252596
Drug: Aerobic interval
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic interval training (AIT) at 85-90% of VO2peak, 3 times weekly for 12 weeks, followed by 2 times weekly for 40 weeks
Study: 24252596
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy diet (800-1000 kcal/day) for 12 weeks followed by weight maintenance combined with supervised AIT twice weekly for 40 weeks
Study: 19477398
Drug: Carvedilol IR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol IR twice daily (BID)
Study: 19477398
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR once daily (QD)
Study: 30932889
Drug: Composite Supplement
Normalized name: DRESSING,COMPOSITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite Supplement Containing Astaxanthin and Sesamin
Study: 30165840
Drug: Negative group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative group (no treatment)
Study: 10829585
Drug: Calcium-antagonists (non
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-antagonists (non dihydropyridinic compounds)
Study: 10829585
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard treatment or placebo)
Study: 1414968
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg beta-carotene/d
Study: 4003667
Drug: Metrifonate treatment
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate treatment (MIT, n = 202)
Study: 28204953
Drug: Aln-NEF alone
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aln-NEF alone (70 mg)
Study: 28204953
Drug: LT4 alone
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 alone (600 μg)
Study: 19497149
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg pre-pregnancy body weight)
Study: 19497149
Drug: Placebo (gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (gelatin capsule)
Study: 16988210
Drug: Desmopressin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin administered as an oral lyophilisate dosage form; specific dosage and duration not mentioned.
Study: 16988210
Drug: Desmopressin in
Normalized name: desmopressin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin in children with nocturnal enuresis; specific dosage and duration not mentioned.
Study: 16988210
Drug: Desmopressin in
Normalized name: desmopressin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin in healthy adults; specific dosage and duration not mentioned.
Study: 15531011
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart injected immediately before the meal
Study: 15531011
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart injected immediately after the meal
Study: 11309011
Drug: 1.0% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% ropivacaine with 50 IU/ml hyaluronidase
Study: 11309011
Drug: 0.75% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% bupivacaine with 50 IU/ml hyaluronidase
Study: 7936311
Drug: deprenyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: deprenyl (10 mg/d)
Study: 5472805
Drug: Pre-exercise inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-exercise inhalation of disodium cromoglycate
Study: 21292872
Drug: Treatment post-infection
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment post-infection
Study: 16303216
Drug: 4th booster
Normalized name: CEPHALOSPORIN 4TH GENERATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4th booster dose of Hib
Study: 12531776
Drug: Once-weekly isoniazid/rifapentine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly isoniazid/rifapentine
Study: 12531776
Drug: Control cases
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cases (not specified but implied to be twice-weekly isoniazid/rifampin)
Study: 12531776
Drug: Twice-weekly isoniazid/rifampin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly isoniazid/rifampin
Study: 2851016
Drug: Enoxaparine 20
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparine 20 mg
Study: 2851016
Drug: Enoxaparine 40
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparine 40 mg
Study: 3344486
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with plain bupivacaine for 48 hours and epidural morphine 4 mg every 8 hours for 96 hours plus systemic indomethacin 100 mg every 8 hours for 96 hours
Study: 3344486
Drug: Conventional postoperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postoperative pain treatment with intermittent nicomorphine (10 to 15 mg) and acetaminophen (1 gm) on request
Study: 27287781
Drug: Atorvastatin at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin at 10, 20, or 40 mg/day for 3 months
Study: 23701177
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) 0.7 mg daily for 40 weeks
Study: 3074463
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg orally b.i.d. for seven days
Study: 3074463
Drug: Co-trimoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (160 mg of trimethoprim plus 800 mg of sulphamethoxazole) orally b.i.d. for seven days
Study: 23333902
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg vs 80 mg
Study: 21540876
Drug: 20% blackcurrant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% blackcurrant juice drink (250 ml)
Study: 19417960
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.5% levobupivacaine
Study: 19417960
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.5% bupivacaine
Study: 17558046
Drug: Niosomal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Niosomal methotrexate gel
Study: 17558046
Drug: Marketed methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Marketed methotrexate gel
Study: 11851027
Drug: Mitoxantrone 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 12 mg/m2 (n = 28)
Study: 11851027
Drug: Methylprednisolone 1
Normalized name: methylprednisolone 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 1 g (n = 21)
Study: 9657119
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 6 MU rIFN-alpha plus 14 mg/kg ribavirin
Study: 31042696
Drug: MDMA (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (0.75 or 1.5 mg/kg)
Study: 31042696
Drug: MA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA (20 mg)
Study: 20368377
Drug: Ayurvedic zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic zinc tablet (jasad bhasma)
Study: 9692071
Drug: Fluoride (sodium
Normalized name: fluoride (sodium) 2.3 % DENTAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride (sodium fluoride 50 mg/day or monofluorophosphate 200 mg/day or 150 mg/day)
Study: 9692071
Drug: Calcium-vitamin D
Normalized name: Calcium-Vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-vitamin D (1 g of calcium and 800 IU of vitamin D2 daily)
Study: 8820898
Drug: Downhill running
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Downhill running at 2.0 mmol.l‐1 [La‐]b
Study: 8820898
Drug: Level running
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level running at 2.0 mmol.l‐1 [La‐]b
Study: 8820898
Drug: Uphill running
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uphill running at 2.0 mmol.l‐1 [La‐]b
Study: 8820898
Drug: Treadmill speed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treadmill speed at 4.0 mmol.l‐1 [La‐]b
Study: 8820898
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of treadmill speed with RPE at 2.0 mmol.l‐1 [La‐]b
Study: 2389831
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg/twice daily for 21 days)
Study: 6273020
Drug: Cortisone acetate
Normalized name: Cortisone Acetate
DrugBank: Cortisone (DB14681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cortisone acetate (25 mg)
Study: 25970751
Drug: 250 g
Normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 g bilberries daily for 7 days
Study: 25970751
Drug: 500 g
Normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 g bilberries daily for 7 days
Study: 25188752
Drug: ACCESS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACCESS treatment model (integrated care including therapeutic assertive community treatment)
Study: 18576295
Drug: Chicken type
Normalized name: Chicken
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicken type II collagen (CCII) 0.1 mg/day
Study: 10788542
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 10 mg/week
Study: 15811207
Drug: Zolmitriptan 2.5
Normalized name: zolmitriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 2.5 mg ODT
Study: 25693652
Drug: 1.2-mL bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2-mL bolus injection over 5 s
Study: 25693652
Drug: 3.5-mL injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5-mL injection over 1 min
Study: 25693652
Drug: 3.5-mL injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5-mL injection over 4 min
Study: 25693652
Drug: 3.5-mL injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5-mL injection over 10 min
Study: 25693652
Drug: 3.5-mL injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5-mL injections
Study: 25693652
Drug: 1.2-mL injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2-mL injections
Study: 25693652
Drug: 4-min injections
Normalized name: gallamine
DrugBank: Gallamine (DB13584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-min injections
Study: 25693652
Drug: 1-min injections
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-min injections
Study: 25693652
Drug: 10-min injections
Normalized name: fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-min injections
Study: 21718484
Drug: Ginseng capsule
Normalized name: Nature's Way Asian Ginseng Capsules
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng capsule (100 mg) twice daily for 24 weeks
Study: 21718484
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo twice daily for 24 weeks
Study: 18829631
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone phosphate
Study: 8418403
Drug: Nucleus multichannel
Normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleus multichannel implant (implant 2)
Study: 8418403
Drug: Ineraid multichannel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ineraid multichannel implant (implant 1)
Study: 8418403
Drug: 3M/Vienna single‐channel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3M/Vienna single‐channel implant (implant 3)
Study: 8418403
Drug: Nucleus multichannel
Normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleus multichannel implant (implant 2) with improved speech processor
Study: 26663687
Drug: mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirabegron 50 mg
Study: 26663687
Drug: mirabegron 100
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mirabegron 100 mg
Study: 31526207
Drug: Ketamine (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.25, 0.5, 1 mg/kg) administered at weekly intervals
Study: 31526207
Drug: Midazolam (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.01 mg/kg)
Study: 20890176
Drug: Thrombolysis (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis (100 mg of alteplase: 10 mg bolus followed by 90 mg intravenous infusion over 2 hours)
Study: 20890176
Drug: Thrombolysis (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis (100 mg of alteplase)
Study: 3536261
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg methylprednisolone
Study: 3536261
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg methylprednisolone
Study: 30146282
Drug: 125 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 g/d of regular cheese for 2 weeks
Study: 20546674
Drug: BMMC injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMMC injection into the left ventricular free wall
Study: 30089135
Drug: Galantamine 4
Normalized name: galantamine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 4 mg
Study: 30089135
Drug: Galantamine 8
Normalized name: galantamine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 8 mg
Study: 12211216
Drug: Galantamine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (4 mg and 8 mg)
Study: 492050
Drug: Propranolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.1 mg/kg)
Study: 8831364
Drug: Procainamide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (15 mg/kg)
Study: 2008800
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with a highly purified, inactivated virus particle vaccine
Study: 26088378
Drug: Ivabradine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 10 mg or 15 mg
Study: 24759957
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment plus a theory‐based behaviour change intervention led by a facilitator
Study: 22689805
Drug: Decitabine 20
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 20 mg/m² per day as a 1-hour intravenous infusion for five consecutive days every 4 weeks
Study: 22689805
Drug: Treatment choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment choice (TC) - supportive care or cytarabine 20 mg/m² per day as a subcutaneous injection for 10 consecutive days every 4 weeks
Study: 22689805
Drug: Treatment choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment choice (TC)
Study: 19424073
Drug: Gabapentin (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1.2 g oral, single dose 1 hour before surgery)
Study: 16697113
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy regimen including active exercises (10 appointments within 14 days)
Study: 16697113
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (immobilization with a soft collar for 7 days)
Study: 15265256
Drug: Abacavir (ABC)
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abacavir (ABC) 300 mg plus fixed-dose lamivudine 150 mg/zidovudine 300 mg (COM) twice daily